# A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

> **NCT03649971** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 77 (actual)

## Conditions studied

- Adenomatous Polyposis Coli

## Interventions

- **DRUG:** Guselkumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03649971
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-19
- **Primary completion:** 2021-09-13
- **Final completion:** 2022-03-23
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03649971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03649971, "A Study of Guselkumab in Participants With Familial Adenomatous Polyposis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03649971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*